Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Newsroom
At Memorial Sloan Kettering Cancer Center, our world-renowned cancer researchers, oncologists, clinicians, and scientists are constantly advancing our knowledge about cancer. Our discoveries are improving treatment and care for patients here and all over the world. On this page, you will find news & information about our latest groundbreaking cancer science, exceptional patient care and the dedicated professionals who make it all happen.
For Journalists
Connect with us to reach MSK experts for media inquiries and for story ideas.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.
Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.
New data presented today by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran, continues to show potential to stimulate an immune response that may reduce the risk of the disease returning after surgery.
Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery during the American Association for Cancer Research (AACR) Annual Meeting on April 5-10 in San Diego, California.
Kieran Healy was feeling worse by the day. A new father at 43 years old, he was bone-tired and losing weight. He had night sweats and a strange lump in his belly. His local hospital in Manhattan ordered an ultrasound and a CT (computed tomography) scan — but they were scheduled over a month away.
Learn how a heralded clinical trial that made rectal cancer disappear for every participant is being expanded at Memorial Sloan Kettering Cancer Center. The trial uses only immunotherapy that targets a rare mutation — without the need for surgery, chemotherapy, or radiation.
MSK-led research could change the practice of medicine for millions of people whose breast cancer has spread. Research led by Dr. Shanu Modi has demonstrated that a targeted drug called trastuzumab deruxtecan blocks the protein HER2 even when its levels are low — the case for about 55% of people with breast cancer.
The protein made by the p53 gene helps guard the body against cancer, in part by detecting and repairing damaged DNA. Over the 30 years since p53 was first discovered, it has remained a stubborn mystery, resisting efforts to tease apart exactly how the loss of the gene’s protection leads to the development of cancer. In August 2022, researchers in the Sloan Kettering Institute were able to provide some new answers that hint at new avenues for treatment.
Cancer Straight Talk brings together national experts and cancer patients to have straightforward, evidence-based conversations. Medical oncologist Diane Reidy-Lagunes hosts this series with the mission of educating and empowering patients to make the right decisions and live happier, healthier lives.
